Paiva et al. of the PETHEMA group reported on a cohort of 233 newly diagnosed MM patients, with CD81+ MM patients having a significantly shorter PFS (3-year rates of 26% vs. 52%, in CD81+ vs. CD81−, respectively), which translated to a significantly shorter OS [90]. Here, CD81 is linked to Miyoshi myopathy.